Susann-Cathrin Schüle1, Thomas Kurt Eigentler2, Claus Garbe2, Christian la Fougère3, Konstantin Nikolaou1, Christina Pfannenberg4. 1. Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University Tuebingen, Hoppe-Seyler-Strasse 3, 72076, Tuebingen, Germany. 2. Skin Cancer Programme, Department of Dermatology, Eberhard-Karls-University Tuebingen, Tuebingen, Germany. 3. Department of Nuclear Medicine, Eberhard-Karls-University Tuebingen, Tuebingen, Germany. 4. Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University Tuebingen, Hoppe-Seyler-Strasse 3, 72076, Tuebingen, Germany. christina.pfannenberg@med.uni-tuebingen.de.
Abstract
PURPOSE: To evaluate the influence of (18)F-FDG PET/CT in comparison to CT alone on treatment decisions in patients with advanced melanoma and to analyse the 5-year survival data in comparison to literature data. METHODS: Therapy management in 64 consecutive patients (primary staging n = 52; surveillance n = 12) with stage III/IV melanoma who underwent (18)F-FDG PET/CT between 2004 and 2005 in our department was retrospectively analysed. Treatment decisions were made by two dermatooncologists for each patient twice, first based on the CT results and then based on the PET/CT results. Therapy changes based on the PET/CT results were classified as "major" (e.g. change from metastasectomy to systemic therapy) or "minor" (e.g. change from first to second line chemotherapy). The 5-year survival data of different patient cohorts were calculated. RESULTS: In the 52 patients in the primary staging group, the results of (18)F-FDG PET/CT led to therapy change in 59% and a major therapy change in 52%. (18)F-FDG PET/CT led to the avoidance of futile operations in 13 patients with suspicious lesions on CT that were deemed nontumorous on PET/CT. In the 12 patients in the surveillance group, the results of (18)F-FDG PET/CT led to therapy change in 33% and a major change in 17%. The 5-year survival rates were 30% in the entire cohort, 34% in the primary staging group, and 17% in the surveillance group. A significant overall survival benefit was observed in patients in whom (18)F-FDG PET/CT excluded metastases or in whom metastases could be completely removed compared with patients who were not eligible for surgery (41% vs. 10%). CONCLUSION: Primary staging of patients with stage III/IV melanoma should be performed with (18)F-FDG PET/CT, leading to higher diagnostic accuracy and enabling individualized therapeutic management, especially optimal patient selection for metastasectomy. This strategy may extend long-term survival even in patients with advanced disease.
PURPOSE: To evaluate the influence of (18)F-FDG PET/CT in comparison to CT alone on treatment decisions in patients with advanced melanoma and to analyse the 5-year survival data in comparison to literature data. METHODS: Therapy management in 64 consecutive patients (primary staging n = 52; surveillance n = 12) with stage III/IV melanoma who underwent (18)F-FDG PET/CT between 2004 and 2005 in our department was retrospectively analysed. Treatment decisions were made by two dermatooncologists for each patient twice, first based on the CT results and then based on the PET/CT results. Therapy changes based on the PET/CT results were classified as "major" (e.g. change from metastasectomy to systemic therapy) or "minor" (e.g. change from first to second line chemotherapy). The 5-year survival data of different patient cohorts were calculated. RESULTS: In the 52 patients in the primary staging group, the results of (18)F-FDG PET/CT led to therapy change in 59% and a major therapy change in 52%. (18)F-FDG PET/CT led to the avoidance of futile operations in 13 patients with suspicious lesions on CT that were deemed nontumorous on PET/CT. In the 12 patients in the surveillance group, the results of (18)F-FDG PET/CT led to therapy change in 33% and a major change in 17%. The 5-year survival rates were 30% in the entire cohort, 34% in the primary staging group, and 17% in the surveillance group. A significant overall survival benefit was observed in patients in whom (18)F-FDG PET/CT excluded metastases or in whom metastases could be completely removed compared with patients who were not eligible for surgery (41% vs. 10%). CONCLUSION: Primary staging of patients with stage III/IV melanoma should be performed with (18)F-FDG PET/CT, leading to higher diagnostic accuracy and enabling individualized therapeutic management, especially optimal patient selection for metastasectomy. This strategy may extend long-term survival even in patients with advanced disease.
Authors: Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf Journal: N Engl J Med Date: 2012-06-04 Impact factor: 91.245
Authors: Annette Pflugfelder; Corinna Kochs; Andreas Blum; Marcus Capellaro; Christina Czeschik; Therese Dettenborn; Dorothee Dill; Edgar Dippel; Thomas Eigentler; Petra Feyer; Markus Follmann; Bernhard Frerich; Maria-Katharina Ganten; Jan Gärtner; Ralf Gutzmer; Jessica Hassel; Axel Hauschild; Peter Hohenberger; Jutta Hübner; Martin Kaatz; Ulrich R Kleeberg; Oliver Kölbl; Rolf-Dieter Kortmann; Albrecht Krause-Bergmann; Peter Kurschat; Ulrike Leiter; Hartmut Link; Carmen Loquai; Christoph Löser; Andreas Mackensen; Friedegund Meier; Peter Mohr; Matthias Möhrle; Dorothee Nashan; Sven Reske; Christian Rose; Christian Sander; Imke Satzger; Meinhard Schiller; Heinz-Peter Schlemmer; Gerhard Strittmatter; Cord Sunderkötter; Lothar Swoboda; Uwe Trefzer; Raymond Voltz; Dirk Vordermark; Michael Weichenthal; Andreas Werner; Simone Wesselmann; Ansgar J Weyergraf; Wolfgang Wick; Claus Garbe; Dirk Schadendorf Journal: J Dtsch Dermatol Ges Date: 2013-08 Impact factor: 5.584
Authors: Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean Jacques Grob; Vanna Chiarion Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymyr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Michelle Casey; Daniele Ouellet; Anne-Marie Martin; Ngocdiep Le; Kiran Patel; Keith Flaherty Journal: N Engl J Med Date: 2014-09-29 Impact factor: 91.245
Authors: Yan Xing; Yulia Bronstein; Merrick I Ross; Robert L Askew; Jeffrey E Lee; Jeffrey E Gershenwald; Richard Royal; Janice N Cormier Journal: J Natl Cancer Inst Date: 2010-11-16 Impact factor: 13.506
Authors: B Weide; M Elsässer; P Büttner; A Pflugfelder; U Leiter; T K Eigentler; J Bauer; M Witte; F Meier; C Garbe Journal: Br J Cancer Date: 2012-07-10 Impact factor: 7.640
Authors: Andrea Forschner; Susann-Cathrin Olthof; Brigitte Gückel; Peter Martus; Werner Vach; Christian la Fougère; Konstantin Nikolaou; Ulrike Keim; Thomas Kurt Eigentler; Claus Garbe; Christina Pfannenberg Journal: Eur J Nucl Med Mol Imaging Date: 2017-03-18 Impact factor: 9.236
Authors: Jacqueline Dinnes; Lavinia Ferrante di Ruffano; Yemisi Takwoingi; Seau Tak Cheung; Paul Nathan; Rubeta N Matin; Naomi Chuchu; Sue Ann Chan; Alana Durack; Susan E Bayliss; Abha Gulati; Lopa Patel; Clare Davenport; Kathie Godfrey; Manil Subesinghe; Zoe Traill; Jonathan J Deeks; Hywel C Williams Journal: Cochrane Database Syst Rev Date: 2019-07-01
Authors: Claudius Falch; Sven Mueller; Andreas Kirschniak; Manuel Braun; Alfred Koenigsrainer; Bernhard Klumpp Journal: World J Surg Oncol Date: 2016-07-15 Impact factor: 2.754